Small Molecules

07 Jun 2007 Anacor clinical study of AN2728, a novel anti-inflammatory compound, shows efficacy in psoriasis
07 Jun 2007 Movetis Announces Start of a Phase IIa Trial for M0002 in Ascites
07 Jun 2007 Surface Logix Starts Phase 2a Clinical Trial of SLx-4090 in Dyslipidemia
07 Jun 2007 Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
06 Jun 2007 Phase 2 results for EentreMmed’s Ppanzem® NCD brain cancer study presented at ASCO
06 Jun 2007 Biovitrum terminates preclinical program in obesity. All rights are returned by GlaxoSmithKline
06 Jun 2007 Sunesis Pharmaceuticals Receives Preclinical Milestone Payment from SARcode Corporation
05 Jun 2007 Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
05 Jun 2007 Phase III Ixabepilone Study Demonstrated Significant Improvement in Progression-Free Survival in Patients With Advanced Metastatic Breast Cancer
05 Jun 2007 Single-Agent SUTENT Prolonged Progression-Free Survival across All Advanced Kidney Cancer Patient Risk Groups, Including Those with Poorest Prognoses, Data Show
05 Jun 2007 Cardiome and Astellas Announce Positive Results from ACT 2 Trial
05 Jun 2007 Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
05 Jun 2007 Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
05 Jun 2007 New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
05 Jun 2007 Cytokinetics Announces the Presentation of Clinical Trials Data at the 2007 Annual Meeting of the American Society of Clinical Oncology
05 Jun 2007 Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial
05 Jun 2007 GW Commences Phase I Study of THCV, a Potential Treatment for Obesity and Related Metabolic Disorders
05 Jun 2007 Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
05 Jun 2007 Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
05 Jun 2007 Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
05 Jun 2007 NPS Announces Progression of the Calcilytics Development Program in Osteoporosis by GlaxoSmithKline
05 Jun 2007 ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
04 Jun 2007 Tapestry Pharmaceuticals presents Phase I data on TPI 287 at the 43rd ASCO Annual Meeting
04 Jun 2007 Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
04 Jun 2007 Vical Demonstrates Safety and Tolerability of IL-2 DNA Delivery with Electroporation

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up